The bicalutamide Early Prostate Cancer Program

American Cancer Society (2000). 2000 facts and figures. Selected cancers: prostate. http://www.cancer.org/statistics/cff2000/selectedcancers.html#prostate. 1992, Lancet, 339, 1 Bolla, 1997, Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin, N Engl J Med, 337, 295, 10.1056/NEJM199707313370502 Pilepich, 1997, Phase III trial of androgen suppression using goserelin in unfavourable prognosis carcinoma of the prostate treated with definitive radiotherapy–report of RTOG protocol 85–31, J Clin Oncol, 15, 1013, 10.1200/JCO.1997.15.3.1013 Messing, 1999, Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadectomy in men with node-positive prostate cancer, N Engl J Med, 341, 1781, 10.1056/NEJM199912093412401 Iversen, 2000, Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer, J Urol, 164, 1579, 10.1016/S0022-5347(05)67032-2 Wirth, 1997, Randomized multicenter trial on adjuvant flutamide therapy in locally advanced prostate cancer after radical surgery, Br J Urol, 80, 263(Abs Wirth, 1999, A review of studies of hormonal adjuvant therapy in prostate cancer, Eur Urol, 36, 14, 10.1159/000052338 Steinberg, 1998, An analysis of watchful waiting for clinically localised prostate cancer, J Urol, 159, 1431, 10.1097/00005392-199805000-00003 1997, Immediate versus deferred treatment for advanced prostate cancer, Br J Urol, 79, 235, 10.1046/j.1464-410X.1997.d01-6840.x